Trials / Completed
CompletedNCT00038220
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/ritonavir | |
| DRUG | Efavirenz | |
| DRUG | Lamivudine | |
| DRUG | Tenofovir DF |
Timeline
- Start date
- 2000-07-01
- First posted
- 2002-05-30
- Last updated
- 2006-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00038220. Inclusion in this directory is not an endorsement.